Trial Outcomes & Findings for Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT) (NCT NCT04479787)
NCT ID: NCT04479787
Last Updated: 2025-02-03
Results Overview
Improvement in pain, defined as percentage of patients who report a ≥ 50% decrease on Numeric Rating Scale (NRS).
COMPLETED
NA
270 participants
6 Months
2025-02-03
Participant Flow
The first patient enrolled in July 2020 was screen failed. Post that, the study enrolled the first subject in September, 2020. In total, 269 subjects were randomized at 30 investigational sites: 162 to SCS and 107 to CMM.
Participant milestones
| Measure |
Spinal Cord Stimulation (SCS)
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
Through 6 Months
STARTED
|
162
|
107
|
|
Through 6 Months
The Number of Subjects Implanted
|
115
|
103
|
|
Through 6 Months
Cross Over to Alternate Arm
|
0
|
70
|
|
Through 6 Months
COMPLETED
|
104
|
85
|
|
Through 6 Months
NOT COMPLETED
|
58
|
22
|
|
After 6 Months
STARTED
|
104
|
85
|
|
After 6 Months
COMPLETED
|
94
|
54
|
|
After 6 Months
NOT COMPLETED
|
10
|
31
|
Reasons for withdrawal
| Measure |
Spinal Cord Stimulation (SCS)
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
Through 6 Months
Withdrawal by Subject
|
16
|
14
|
|
Through 6 Months
Unsuccessful Trial
|
17
|
0
|
|
Through 6 Months
Subject Participation Terminated By Investigator
|
12
|
3
|
|
Through 6 Months
IPG/Lead(s) Explanted But Not Replaced
|
2
|
0
|
|
Through 6 Months
Lost to Follow-up
|
3
|
2
|
|
Through 6 Months
Death
|
3
|
0
|
|
Through 6 Months
Inclusion/Exclusion
|
2
|
1
|
|
Through 6 Months
Subject Became Pregnant
|
1
|
1
|
|
Through 6 Months
Patient Diagnosed With Oral Cancer, Needs To Undergo Radiation And Chemo
|
0
|
1
|
|
Through 6 Months
Withdrawn At Sponsor's Request
|
1
|
0
|
|
Through 6 Months
Subject Failed To Comply With The Protocol Requirements
|
1
|
0
|
|
After 6 Months
Withdrawal by Subject
|
3
|
13
|
|
After 6 Months
Unsuccessful Trial
|
0
|
7
|
|
After 6 Months
IPG/Lead(s) Explanted But Not Replaced
|
2
|
4
|
|
After 6 Months
Subject Participation Terminated By Investigator
|
2
|
2
|
|
After 6 Months
Death
|
2
|
0
|
|
After 6 Months
Lost to Follow-up
|
1
|
1
|
|
After 6 Months
Patient Was Withdrawn Due To Study Timelines
|
0
|
1
|
|
After 6 Months
Patient's Health Significantly Declined
|
0
|
1
|
|
After 6 Months
Subject Had Back Surgery On March 1st
|
0
|
1
|
|
After 6 Months
Subject Failed To Comply With The Protocol Requirements
|
0
|
1
|
Baseline Characteristics
The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
Baseline characteristics by cohort
| Measure |
Spinal Cord Stimulation (SCS)
n=115 Participants
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator.
Spinal Cord Stimulation: Utilization of BURSTDR stimulation.
|
Conventional Medical Management (CMM)
n=103 Participants
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy).
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
Total
n=218 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
58.1 years
STANDARD_DEVIATION 13.0 • n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
59.1 years
STANDARD_DEVIATION 12.4 • n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
58.5 years
STANDARD_DEVIATION 12.8 • n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
|
Sex: Female, Male
Female
|
69 Participants
n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
52 Participants
n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
121 Participants
n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
|
Sex: Female, Male
Male
|
46 Participants
n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
51 Participants
n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
97 Participants
n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
|
Race/Ethnicity, Customized
White
|
96 Participants
n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
84 Participants
n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
180 Participants
n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
|
Race/Ethnicity, Customized
Black or African American
|
7 Participants
n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
3 Participants
n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
10 Participants
n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
|
Race/Ethnicity, Customized
Asian
|
0 Participants
n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
7 Participants
n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
7 Participants
n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
|
Race/Ethnicity, Customized
American Indian or Alaska Native
|
1 Participants
n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
2 Participants
n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
3 Participants
n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
|
Race/Ethnicity, Customized
Declined or Unable to Disclose Due to Local Regulation
|
10 Participants
n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
6 Participants
n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
16 Participants
n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
|
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
0 Participants
n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
1 Participants
n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
|
Race/Ethnicity, Customized
More than one race (One subject having both White and Asian race)
|
0 Participants
n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
1 Participants
n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
1 Participants
n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the demographics questionnaire including age, sex, and race.
|
|
Pain Numeric Rating Scale (NRS)
Lower Back
|
7.7 scores on a scale
STANDARD_DEVIATION 1.2 • n=115 Participants • The number of participants analyzed includes only the implanted patients who completed the questionnaire for Pain Numeric Rating Scale.
|
7.9 scores on a scale
STANDARD_DEVIATION 1.1 • n=103 Participants • The number of participants analyzed includes only the implanted patients who completed the questionnaire for Pain Numeric Rating Scale.
|
7.8 scores on a scale
STANDARD_DEVIATION 1.2 • n=218 Participants • The number of participants analyzed includes only the implanted patients who completed the questionnaire for Pain Numeric Rating Scale.
|
|
Pain Numeric Rating Scale (NRS)
Right Leg
|
2.7 scores on a scale
STANDARD_DEVIATION 2.6 • n=97 Participants • The number of participants analyzed includes only the implanted patients who completed the questionnaire for Pain Numeric Rating Scale.
|
3.1 scores on a scale
STANDARD_DEVIATION 2.8 • n=95 Participants • The number of participants analyzed includes only the implanted patients who completed the questionnaire for Pain Numeric Rating Scale.
|
3.0 scores on a scale
STANDARD_DEVIATION 2.7 • n=192 Participants • The number of participants analyzed includes only the implanted patients who completed the questionnaire for Pain Numeric Rating Scale.
|
|
Pain Numeric Rating Scale (NRS)
Left Leg
|
2.8 scores on a scale
STANDARD_DEVIATION 2.7 • n=100 Participants • The number of participants analyzed includes only the implanted patients who completed the questionnaire for Pain Numeric Rating Scale.
|
3.0 scores on a scale
STANDARD_DEVIATION 2.8 • n=94 Participants • The number of participants analyzed includes only the implanted patients who completed the questionnaire for Pain Numeric Rating Scale.
|
3.0 scores on a scale
STANDARD_DEVIATION 2.8 • n=194 Participants • The number of participants analyzed includes only the implanted patients who completed the questionnaire for Pain Numeric Rating Scale.
|
PRIMARY outcome
Timeframe: 6 MonthsPopulation: Percentage of patients who reported a 50% decrease in NRS pain score.
Improvement in pain, defined as percentage of patients who report a ≥ 50% decrease on Numeric Rating Scale (NRS).
Outcome measures
| Measure |
Spinal Cord Stimulation (SCS)
n=119 Participants
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
n=81 Participants
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
The Difference in Responders Between Both Groups
|
87 participants
|
5 participants
|
SECONDARY outcome
Timeframe: 6 MonthsPopulation: The number of participants analyzed includes subjects who were available at that time of analysis.
Composite Responder rate describes percentage of patients who responded on NRS OR ODI improvements (percentage of patients who report at least ≥13 change on ODI from baseline OR a ≥ 50% decrease in NRS from baseline).
Outcome measures
| Measure |
Spinal Cord Stimulation (SCS)
n=102 Participants
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
n=81 Participants
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
Measure of Composite Responder Rate
|
93 participants
|
13 participants
|
SECONDARY outcome
Timeframe: Baseline to 6 MonthsPopulation: The number of participants analyzed includes subjects who were available at that time of analysis.
The numeric rating scale (NRS) is a verbal or written determination of a pain level on a scale from 0 to 10, in which 0 represents no pain and 10 represents excruciating pain (the worst pain imaginable). Lower scores indicate pain reduction. The data is expressed as relative change (%).
Outcome measures
| Measure |
Spinal Cord Stimulation (SCS)
n=102 Participants
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
n=81 Participants
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
Numerical Rating Scale (NRS) Relative Change From Baseline to 6 Months
|
69.7 percent change
Standard Deviation 24.9
|
5.6 percent change
Standard Deviation 21.3
|
SECONDARY outcome
Timeframe: Baseline to 6 MonthsPopulation: The number of participants analyzed includes subjects who were available at that time of analysis.
The Oswestry Disability Index questionnaire will be completed during selected clinical site visits via the electronic data acquisition portal. These questionnaires will be used for the assessment of study endpoints. An interpretation of 0% to 20% means minimal disability;21% to 40% means moderate disability; 41% to 60% means severe disability; 61% to 80% means crippled; and 81%-100% means bed-bound patients. Lower scores indicate less disability.
Outcome measures
| Measure |
Spinal Cord Stimulation (SCS)
n=98 Participants
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
n=81 Participants
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
Oswestry Disability Index (ODI) Change From Baseline to 6 Months
|
29.4 units on a scale
Standard Deviation 18.8
|
0.7 units on a scale
Standard Deviation 13.0
|
SECONDARY outcome
Timeframe: 6 MonthsPopulation: The number of participants analyzed includes subjects who were available at that time of analysis.
The Pain Catastrophizing Scale questionnaire is a three part question that measures three pain domains: 1. Rumination (e.g. "I can´t stop thinking about how much it hurts") 2. Magnification (e.g. "I´m afraid that something serious might happen") 3. Helplessness (e.g. "There is nothing I can do to reduce the intensity of my pain"). The Pain Catastrophizing Scale questionnaire will be completed during selected clinical site visits via the electronic data acquisition portal. These questionnaires will be used for the assessment of study endpoints. The questionnaire includes 13 statements describing different thoughts and feelings that may be associated with pain. Using the scale 0-4 (0- not at all; 1- to a slight degree; 2- to a moderate degree; 3- to a great degree; and 4- all the time), the patients are expected to indicate the degree to which they have these thoughts and feelings when they're experiencing pain. Lower scores indicate less catastrophizing thoughts.
Outcome measures
| Measure |
Spinal Cord Stimulation (SCS)
n=102 Participants
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
n=81 Participants
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
Pain Catastrophizing Scale (PCS) Responder Rate
|
90 participants
|
19 participants
|
SECONDARY outcome
Timeframe: 6 MonthsPopulation: The number of participants analyzed includes subjects who were available at that time of analysis. PGIC- % of patients who reported "very much improved," or "much improved."
PGIC is a 7 point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse." The percentage of patients who reported "very much improved," or "much improved," are presented.
Outcome measures
| Measure |
Spinal Cord Stimulation (SCS)
n=102 Participants
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
n=81 Participants
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
Patient Global Impression of Change (PGIC) Responder Rate
|
77 participants
|
2 participants
|
SECONDARY outcome
Timeframe: Baseline to 6 MonthsPopulation: The number of participants analyzed includes subjects who were available at that time of analysis.
The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the pain interference domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., worse outcome). Pain Interferences: Normal: \<55; Mild: 55 - 60; Moderate: 60 -70; and Severe: \>70.
Outcome measures
| Measure |
Spinal Cord Stimulation (SCS)
n=102 Participants
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
n=81 Participants
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS-29) Pain Interference Relative Change From Baseline to 6 Months
|
17.9 scores on a scale
Standard Deviation 11.3
|
0.9 scores on a scale
Standard Deviation 9.3
|
SECONDARY outcome
Timeframe: Baseline to 6 MonthsPopulation: The number of participants analyzed includes subjects who were available at that time of analysis.
The PROMIS-29 physical function sub-scale includes 4 questions. The Patient-Reported Outcomes Measurement Information System (PROMIS) 29-item short-form health-reported quality of life measures (PROMIS-29) were administered. The transformed score (T-score) for the physical function domain was used, where 50 (10) is the mean (standard deviation) of a relevant reference population. Higher scores equals more of the concept being measured (i.e., better outcome). Physical function- Normal: \>45; Mild: 40 - 45; Moderate: 30 - 40; and Severe: \>30.
Outcome measures
| Measure |
Spinal Cord Stimulation (SCS)
n=102 Participants
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
n=81 Participants
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
Patient-Reported Outcomes Measurement Information System (PROMIS-29) Physical Function Relative Change From Baseline to 6 Months
|
27.8 scores on a scale
Standard Deviation 24.4
|
1.4 scores on a scale
Standard Deviation 13.6
|
Adverse Events
Spinal Cord Stimulation (SCS)
Conventional Medical Management (CMM)
Serious adverse events
| Measure |
Spinal Cord Stimulation (SCS)
n=162 participants at risk
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
n=107 participants at risk
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
Infections and infestations
Infection
|
1.2%
2/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
Injury, poisoning and procedural complications
Digoxin Toxicity
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
Renal and urinary disorders
Bladder Rupture
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary Edema
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
Surgical and medical procedures
Numbness Below The Level Of Implant
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
Surgical and medical procedures
Post Surgical Pain
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
Other adverse events
| Measure |
Spinal Cord Stimulation (SCS)
n=162 participants at risk
An SCS Trial period followed by SCS Implantation with the Abbott Proclaim XR Implantable Pulse Generator
Spinal Cord Stimulation: Utilization of BURSTDR stimulation
|
Conventional Medical Management (CMM)
n=107 participants at risk
CMM consists of an array of therapies including, but not limited to structured physical therapy, medications, injections, and complementary and alternative medicine (e.g. acupuncture, massage therapy)
Conventional Medical Management: Assessing type of CMM, location and frequency.
|
|---|---|---|
|
General disorders
Persistent Pain At The IPG Site
|
1.9%
3/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
Skin and subcutaneous tissue disorders
Skin Reaction
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
Infections and infestations
Infection
|
1.9%
3/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
General disorders
Sleeping Issues And Weird Dreams
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
Nervous system disorders
Cerebrospinal Fluid (CSF) Leakage
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
Product Issues
Changes In Stimulation Or Reduced Pain Relief Due To Lead Migration
|
2.5%
4/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
General disorders
Damage To The IPG Or Leads
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
Skin and subcutaneous tissue disorders
Dermatitis And Desquamation
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
General disorders
Implant Migration
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
|
General disorders
Movement Or Vibration Of The IPG Or Leads
|
0.62%
1/162 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
0.00%
0/107 • 6 months
The CMM arm did not report any adverse event. The adverse events provided are all reported for the SCS arm.
|
Additional Information
Devyani Nanduri, Sr. Director, Clinical and Regulatory Affairs
Abbott
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60